Osteoarthritis is a localized disease in that OA is not generally present throughout the body, and only affects certain joints. This compartmental aspect of the disease avails it to treatment that is targeted to the site in which the disease resides. In order to limit bodywide exposure to an osteoarthritis drug, the affected joint is often directly injected in a procedure called intraarticular injection. The Calosyn approach to osteoarthritis is intraarticular injection of a calcium channel blocker.

Calcium channel blockers are a class of drugs with a long history of safety in the treatment of cardiovascular diseases, though they have never been used in osteoarthritis. Through our own research, and that of other scientists around the world, a great deal has been learned about how these drugs work, and how osteoarthritis destroys tissue in the joints and causes joint pain. Calosyn’s scientists discovered that osteoarthritic joints are abnormal in the way they use calcium, and that blocking calcium inside an osteoarthritic joint has a profound impact on pain, and may modify the course of the osteoarthritic disease.

Calosyn Pharma is conducting clinical trials of its product in the United States. If you are interested in this clinical trial, please find the trial at www.clinicaltrials.gov and contact the trial administrators.

WARNING: THIS PRODUCT IS UNDER STUDY AND NOT CURRENTLY APPROVED FOR USE IN HUMANS OUTSIDE OF APPROVED CLINICAL TRIALS